You are currently viewing the editor's summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Creating an effective duo
The drug nerinetide exerts neuroprotective effects in stroke by interfering with the postsynaptic density protein PSD-95. However, in patients, nerinetide lost the therapeutic effects when administered with (or after) the tissue plasminogen activator alteplase. Here, Mayor-Nunez et al. investigated the interaction between nerinetide and alteplase in rodents and showed that plasmin, activated by alteplase, cleaved nerinetide. Administering nerinetide 30 min or more before alteplase avoided the cleavage and restored the therapeutic effect of nerinetide. Moreover, the authors developed a protease-insensitive nerinetide by changing the enantiomeric form of cleavage-sensitive amino acids. The results identified two feasible strategies that might improve the efficacy of nerinetide in combination with tissue plasminogen activators in patients after stroke.
- Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
This is an article distributed under the terms of the Science Journals Default License.
